374 related articles for article (PubMed ID: 21707463)
1. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity.
Steiner J; Bogerts B; Sarnyai Z; Walter M; Gos T; Bernstein HG; Myint AM
World J Biol Psychiatry; 2012 Oct; 13(7):482-92. PubMed ID: 21707463
[TBL] [Abstract][Full Text] [Related]
2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
3. Kynurenines: from the perspective of major psychiatric disorders.
Myint AM
FEBS J; 2012 Apr; 279(8):1375-85. PubMed ID: 22404766
[TBL] [Abstract][Full Text] [Related]
4. Induction of the kynurenine pathway by neurotropic influenza A virus infection.
Holtze M; Asp L; Schwieler L; Engberg G; Karlsson H
J Neurosci Res; 2008 Dec; 86(16):3674-83. PubMed ID: 18655201
[TBL] [Abstract][Full Text] [Related]
5. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence.
Müller N
Curr Opin Investig Drugs; 2010 Jan; 11(1):31-42. PubMed ID: 20047157
[TBL] [Abstract][Full Text] [Related]
6. COX-2 inhibition in schizophrenia and major depression.
Müller N; Schwarz MJ
Curr Pharm Des; 2008; 14(14):1452-65. PubMed ID: 18537668
[TBL] [Abstract][Full Text] [Related]
7. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
8. The role of the mGluR allosteric modulation in the NMDA-hypofunction model of schizophrenia.
Doreulee N; Alania M; Mitaishvili E; Chikovani M; Chkhartishvili B
Georgian Med News; 2009 Dec; (177):59-65. PubMed ID: 20090156
[TBL] [Abstract][Full Text] [Related]
9. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis.
Steiner J; Walter M; Glanz W; Sarnyai Z; Bernstein HG; Vielhaber S; Kästner A; Skalej M; Jordan W; Schiltz K; Klingbeil C; Wandinger KP; Bogerts B; Stoecker W
JAMA Psychiatry; 2013 Mar; 70(3):271-8. PubMed ID: 23344076
[TBL] [Abstract][Full Text] [Related]
10. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.
Muller N; Schwarz M
Neurotox Res; 2006 Oct; 10(2):131-48. PubMed ID: 17062375
[TBL] [Abstract][Full Text] [Related]
11. Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders.
Müller N; Schwarz MJ
Expert Rev Neurother; 2006 Jul; 6(7):1017-38. PubMed ID: 16831116
[TBL] [Abstract][Full Text] [Related]
12. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality.
Bay-Richter C; Linderholm KR; Lim CK; Samuelsson M; Träskman-Bendz L; Guillemin GJ; Erhardt S; Brundin L
Brain Behav Immun; 2015 Jan; 43():110-7. PubMed ID: 25124710
[TBL] [Abstract][Full Text] [Related]
13. Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects.
Müller N; Myint AM; Schwarz MJ
Curr Pharm Des; 2011; 17(2):130-6. PubMed ID: 21361867
[TBL] [Abstract][Full Text] [Related]
14. Serum kynurenic acid is reduced in affective psychosis.
Wurfel BE; Drevets WC; Bliss SA; McMillin JR; Suzuki H; Ford BN; Morris HM; Teague TK; Dantzer R; Savitz JB
Transl Psychiatry; 2017 May; 7(5):e1115. PubMed ID: 28463241
[TBL] [Abstract][Full Text] [Related]
15. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression.
Müller N; Schwarz MJ
Mol Psychiatry; 2007 Nov; 12(11):988-1000. PubMed ID: 17457312
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of glutamate in the pathophysiology of major depressive disorder.
Hashimoto K
Brain Res Rev; 2009 Oct; 61(2):105-23. PubMed ID: 19481572
[TBL] [Abstract][Full Text] [Related]
17. Glutamatergic aspects of schizophrenia.
Tamminga C
Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
[TBL] [Abstract][Full Text] [Related]
18. Contributions of the D-serine pathway to schizophrenia.
Labrie V; Wong AH; Roder JC
Neuropharmacology; 2012 Mar; 62(3):1484-503. PubMed ID: 21295046
[TBL] [Abstract][Full Text] [Related]
19. The acute effects of NMDA antagonism: from the rodent to the human brain.
Gunduz-Bruce H
Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
[TBL] [Abstract][Full Text] [Related]
20. [Role of excitatory amino acids in neuropathology].
Wikinski SI; Acosta GB
Medicina (B Aires); 1995; 55(4):355-65. PubMed ID: 8728878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
